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Background: Cervical cancer is the second most frequent cancer among woman worldwide and is considered to be caused by infection with high-risk papilloma viruses. Genetic immunization using recombinant adenoassociated virus (rAAV) vectors has shown great promise for vaccination against human papillomavirus (HPV) infections. Methods: rAAV5, -8 and -9 vectors expressing an HPV16 L1/E7 fusion gene were generated and applied intranasally for combined prophylactic and therapeutic vaccination of mice. Results: The rAAV5 and the rAAV9 vectors showed efficient induction of both humoral and cellular immune responses, whereas rAAV8 failed to immunize mice by the intranasal route. The L1-specific immune response evoked by expression of the L1/E7 fusion gene, however, was lower than that evoked by expression of the L1 antigen alone. This deficiency could be compensated by application of Escherichia coli heat-labile enterotoxin or monophsphoryl lipid as adjuvant upon vaccination with rAAV5-L1/E7. Coimmunization of rAAV9-L1/E7 with rAAV5-L1 or boosting of rAAV9-L1/E7 with rAAV5-L1 strongly increased L1-specific neutralizing antibody titres to levels above those achieved by vaccination with vectors expressing L1 alone. Both vectors elicited a vibrant cytotoxic T-lymphocyte response against L1 or E7. Nasal immunization with rAAV5 or rAAV9 was superior to vaccination with HPV16-L1 virus-like particles (VLPs) or HPV16-L1/E7 CVLPs with respect to humoral and cellular immune responses. Vaccination with the rAAV vectors led to a significant protection of animals against a challenge with different HPV tumour cell lines. Conclusions: Our results show that rAAV5 and rAAV9 vectors are promising candidates for a non-invasive nasal vaccination strategy.
Cervical cancer is the second most common cancer among women worldwide. Persistent high-risk human papillomavirus (HPV) infection has been identified as a necessary event for the development of this type of cancer [1] . Recently, two HPV vaccines against the most important HPV types (16 and 18) with a remarkable safety profile and clinical efficacy have been licensed. They consist of virus-like particles (VLPs) assembled from the major capsid protein L1 and, by the aid of neutralizing antibodies, are expected to prevent up to 70% of cervical cancer cases. Because there is an existing and considerable burden of present infections, it is estimated that it would take decades for preventive vaccination to reduce cervical cancer rates. Furthermore, these vaccines are expensive to produce and require refrigeration for storage and needles for injection; thus, limiting their application in developing countries.
Future vaccines should therefore attempt to extend immunization against other high-risk HPV types, to combine preventive and therapeutic properties, to consist of a temperature stable formulation and to allow delivery by a non-invasive manner.
The cellular immune response to HPV gene products appears to play an important role in controlling HPV infection and associated disease [2] . HPV E6 and E7 viral oncoproteins have been the main candidate targets for therapeutic vaccination strategies against cervical neoplasia because they are consistently expressed in (pre)malignant cells [3] [4] [5] . Chimeric virus-like particles (CVLPs) consisting of a truncated HPV16 L1 fused with a portion of E7 have been analysed in mice. A strong antitumour response was obtained, which was conferred by a CD8 + T-cell-mediated cellular immune response [6] [7] [8] [9] . A Phase I/II clinical trial in women Introduction with high-grade cervical dysplasia demonstrated safety and immunogenicity in most of the patients [10] ; however, the trial was not powered to determine clinical efficacy. We previously described that in DNA immunization experiments with a slightly different C-terminal truncated HPV16 L1 protein fused to the first 60 amino acids of E7 elicited a humoral immune response against viral capsids and a cellular immune response against L1 and E7 [11] .
Recombinant adeno-associated virus vectors (rAAV) are promising candidates for gene therapy and vectorbased vaccination because of their lack of pathogenicity and their ability to establish long-term transgene expression (for reviews see [12] [13] [14] ). rAAVs have the potential to be delivered needle-free, which would overcome one of the challenges for vaccine delivery in the developing world [15] [16] [17] [18] . In a previous study, we demonstrated that a single dose of rAAV5-L1 administered intranasally was sufficient to induce high titres of L1-specific serum antibodies, as well as mucosal antibodies in vaginal washes [16] . Seropositivity and cytotoxic T-lymphocyte (CTL) immune response were maintained for >1 year. A major problem in humans is the presence of anti-AAV antibodies that effectively neutralize the gene therapeutic vector; however, switching capsid serotypes might overcome this problem. To date, 13 different serotypes (designated AAV1-13) and >100 cap variants have been isolated from humans or non-human primates [19, 20] .
The aim of this study was to develop an rAAV-based vaccine with prophylactic and therapeutic properties that can be applied by the intranasal route.
Methods
Mice and cell lines C57BL/6 (H-2 b ) female mice (6-8 weeks of age) were purchased from Charles River Wiga (Sulzfeld, Germany) and kept in an isolator at the animal facilities of the German Cancer Research Center (Heidelberg, Germany). The mice were housed in accordance to the institutional guidelines. HeLa and 293T cells were cultured as described previously [11] .
Vaccine vector production and purification 293T cells were cotransfected with the packaging plasmid to produce pseudotyped rAAV2/5 (pDP5), [21] rAAV2/8 and rAAV2/9 [22] and the vector plasmid UF2 green fluorescent protein (GFP), L1h 1-498 /E7 1-60 [11] or UF3 L1h [16] . Processing of cells was done as described previously [16] and the rAAV particles were purified by an iodixanol step gradient followed by a continuous gradient [23] . Virus stock was concentrated in a Vivaspin 20 concentrator (Vivascience, Gottingen, Germany) according to the manufacturer protocol to a titre of 5×10 12 genome-containing particles (gp)/ml and stored frozen at -80°C . From  2×10  8 cells, a total of 2×10  13 gp were obtained in the  crude cell lysate and approximately 1×10 12 gp were routinely recovered after purification. Vector genome titres were determined by quantitative real-time PCR as described previously [16] .
Immunization of mice
Female mice were kept under deep ketamine 10%/ rompun 2% anaesthesia by intraperitoneal injection. An aliquot of 10 µl of viral vector, VLP, CVLP or phosphate-buffered saline (PBS) were delivered dropwise into one nostril. After 7 days, a boost was administrated in the same way. Samples of blood and vaginal washes were collected 6, 9 and 12 weeks after the first immunization. All samples were stored at -20°C.
Adjuvants
Phosphorothioate-stabilized oligonucleotides 1826 (CpG ODN 5′-TCC ATG ACG TTC CTG ACG TT-3′) were obtained from TIB MOLBIOL (Berlin, Germany) and 10 µg were applied per dose. Escherichia coli LT(R192G), a genetically detoxified derivative of the E. coli heat-labile enterotoxin (HLT), was kindly provided by JD Clements (Tulane University, New Orleans, LA, USA). Lyophilized LT(R192G) was reconstituted in sterile PBS (1 mg/ml) and 5 µg were applied per dose. In addition, 5 µg of monophosphoryl lipid A (MPL) derived from Salmonella enterica (Sigma, Steinheim, Germany) were applied per dose.
Measurement of antibody responses
The presence of L1-specific immunoglobulin (Ig)G and IgA antibodies in sera (in twofold dilutions starting from 1:50 to 1:40,480) or vaginal washes (starting from undiluted to 1:265) of immunized mice was determined by VLP ELISA as described previously [6] . To detect anti-rAAV5-or 9-specific IgG antibodies, sera was added into rAAV5 or rAAV9 pre-coated plates (10 10 particles/well) following the same conditions as above. Non-specific binding was determined using the same dilutions on plates coated with PBS only.
ELISPOT assays
The number of L1-and E7-specific CTLs was determined ex vivo by interferon-γ ELISPOT assays as described previously [24] . To measure HPV16 L1-or E7-specific interferon-γ T-lymphocytes, cells were treated with 30 µM of either L1 [165] [166] [167] [168] [169] [170] [171] [172] [173] or with E7 49-57 peptides [8] . Numbers of specific spots per 10 6 cells were determined for each mouse by subtracting the number of spots of the internal negative control (cells incubated with medium alone) from the number of spots after incubation with the appropriate antigen-specific peptide.
Pseudovirion-based neutralization assays
Detection of neutralizing antibodies in sera of immunized animals was determined as described previously [25] . Pseudovirions obtained according to our standard protocol [16] were diluted 1:5000 in Dulbecco's modified Eagle's medium and preincubated with the sera in a 1:50 dilution or in a 1:50-1:100,000 dilution for titration before incubation with the cells and measuring the secreted alkaline phosphatase activity in the supernatant.
Tumour protection
Mice were immunized intranasally either with rAAV5-L1/E7, rAAV9-L1/E7 or PBS. At 9 weeks after the first immunization, mice were challenged subcutaneously into the right flank with 5×10 5 C3 cells in 100 µl PBS under isoflurane anaesthesia. Subsequently, mice were rechallenged subcutaneously into the left flank with 5×10
5 TC-1 cells in 100 µl PBS under isoflurane anaesthesia. Tumour growth was monitored for 3-4 days.
Results
Nasal immunization against HPV16 L1 and L1/E7 antigens using rAAV5, -8 and -9 vectors
In previously published work [16] , we demonstrated that rAAV5-L1 induces long-lasting humoral and cellular immune responses against HPV16 L1 after a single intranasal application. To extend this approach towards the development of an rAAV-based vaccine with combined prophylactic and therapeutic properties, we generated rAAVs expressing an HPV16 L1/E7 fusion protein. The respective fusion gene was based on a construct tested for DNA vaccination, which showed induction of L1-specific antibodies, as well as of L1-and E7-specific CTL responses [11] . In this study, we included vectors based upon rAAV serotypes 8 and 9 to compare their ability for genetic vaccination with the previously evaluated rAAV5.
C57BL/6 mice (five per group) were vaccinated intranasally with two doses of 5×10 10 gp of HPV16 L1/E7 rAAV at a 7-day interval. Mice vaccinated with PBS, rAAV5-, rAAV8-or rAAV9-expressing GFP (each with 5×10 10 gp/dose) were used as negative controls, and immunizations with L1-VLPs (5 µg/dose) or L1/ E7-CVLPs (5 µg/dose) served as positive controls. Sera collected at different time points (6, 9 and 12 weeks after the first vaccination) were analysed by ELISA for HPV16 L1-specific IgG antibodies. In addition, 3 months after the first immunization, the splenocytes were analysed by an ex vivo ELISPOT assay after stimulation with HPV16 L1 or E7 peptides. Table 1 and Figure 1 summarize the results obtained at 3 months after vaccination. Sera of all mice immunized with VLPs or CVLPs had L1-specific antibodies; however, they did not develop significant L1-or E7-specific CTLs ( Figures 1C and 2B ). Interestingly, several subcutaneous immunizations with CVLPs in mice elicited low L1-specific and no E7-specific CTL response (Dr L Schädlich, DKFZ, Heidelberg, Germany, personal communication). Animals vaccinated with rAAV5-L1 or rAAV9-L1 vectors both developed a strong humoral immune response, showing similar antibody titres compared with mice immunized subcuaneously with several doses of VLPs [26] , whereas the L1-specific immune response of animals vaccinated with the L1/ E7 fusion gene was significantly weaker ( Figure 1A ). With rAAV5-L1/E7, only 2 of 10 immunized animals Table 1 . Summary of intranasal immunization against HPV16 L1 and L1/E7 antigens using rAAV serotypes 5, 8 and 9
Sera of C57BL/6 mice were tested for human papillomavirus type-16 (HPV16) L1-specific antibodies using a virus-like particle (VLP)-based ELISA and L1-or E7-specific cytotoxic T-lymphocyte (CTL) response was measured in a standard ELISPOT assay at 3 months after intranasal vaccination with recombinant adenovirus-associated virus (rAAV)5-L1/E7, rAAV8-L1/E7 or rAAV9-L1/E7 with two doses (5×10 10 genome-containing particles/dose) at a 7-day interval. Positive control mice were vaccinated with chimeric virus-like particles (CVLP), VLP or rAAV5-L1. Negative control mice were treated with phosphate-buffered saline (PBS) or rAAV-expressing green fluorescent protein (GFP). Sera of vaccinated mice were also tested for serotype specific rAAV antibodies using an rAAV-based ELISA. Data of two independent experiments are presented as number of positive mice/total number. IFN, interferon; NA, not applicable; ND, not determined. were positive for L1 antibodies and 6 of 10 animals vaccinated with rAAV9-L1/E7 were positive for L1 antibodies. This was also reflected in the lower neutralization activity of these antisera ( Figure 1B ). Because vaccination with rAAV8-L1/E7 did not evoke a measurable anti-L1 immune response ( Figure 1A ), these vectors were not included in a second vaccination experiment. The T-cell response, measured by ELISPOT assays, revealed a positive response of all animals vaccinated with rAAV5 or rAAV9 vectors expressing L1 or L1/E7. In contrast to the humoral immune response, the cellular immune response seemed to be slightly 100,000
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10,000 weaker in animals vaccinated with rAAV9 vectors as compared with animals vaccinated with rAAV5 vectors ( Figure 1A and 1C) . All animals immunized with rAAVs showed an antibody response to the AAV capsids (Table  1) , although the immune response to rAAV9 was relatively weak (reciprocal titre was approximately 10,000 as compared with 100,000-500,000 for rAAV5). Analysis of several organs showed that transgene expression and vector DNA was detected in lung tissue, but not in other organs after intranasal application with those serotypes (data not shown). Taken together, the results demonstrate that expression of the L1 transgene induced more efficiently L1-specific antibodies than expression of the L1/E7 fusion gene. They also suggest that rAAV9 provides a stronger immune response than rAAV5. Because vaccination with rAAV9 has not been reported so far, we directly compared the vaccination efficiency of serotype rAAV5 and rAAV9 vectors expressing the L1 gene in more detail including also an analysis of mucosal immunity.
Comparison of vaccination with rAAV5-L1 and rAAV9-L1
Mice were immunized twice intranasally with rAAV5 or rAAV9 vectors (n=5 per group) expressing L1 (5×10 10 gp/ dose) and the humoral immune response was compared with immunization with VLPs at 6, 9 and 12 weeks after the first immunization ( Figure 3 ). As shown in Figure 3A , at 12 weeks post-vaccination, mice immunized with serotype 9 had developed a twofold higher titre of L1-specific serum antibodies than mice immunized with rAAV5. Importantly, the immune response following vaccination with both rAAVs, although initially lower than in VLP-immunized mice, increased over time and persisted longer than following immunization with VLPs. The stronger humoral immune response obtained with the rAAV vaccination was also reflected by the higher neutralization activity obtained with the antisera from animals immunized with rAAV5-L1 or rAAV9-L1 ( Figure 3C) .
Vaginal washes were also tested for L1-specific IgG and IgA antibodies ( Figure 3B ). The presence of these two Ig types differed between the three vaccination groups. Although IgG levels were clearly higher in animals vaccinated with rAAV5-L1 and rAAV9-L1 compared with animals vaccinated by VLPs, mucosal IgA was only detectable in the groups vaccinated with rAAV9-L1 or VLPs. The group of animals immunized with rAAV5-L1 showed no mucosal IgA production. These data together support a higher efficiency of rAAV9 to induce humoral immune responses in the nasal vaccination approach.
Influence of adjuvant on vaccination with rAAVs
Because combined prophylactic and therapeutic vaccination with L1/E7 fusion genes was less efficient than vaccination with L1 alone, we wanted to explore whether the immunogenicity of the L1/E7-expressing vectors could be enhanced by the use of an adjuvant. We selected CpG DNA, R192G, a genetically detoxified derivative of the E. coli HLT [27] and MPL. A total of five C57BL/6 mice per group were immunized intranasally with rAAV5-L1/E7 or rAAV9-L1/E7 (5×10 10 gp/ dose) without or together with one of the adjuvants. Of the five mice, three were immunized with rAAV5-GFP or rAAV9-GFP (5×10 10 gp/dose) and two were immunized with the mixture of adjuvant only, which were used as a negative control. L1-VLP immunized mice (n=5) were used as positive controls. Sera were tested at 12 weeks after the first immunization. Mice immunized with rAAV5-L1/E7 without adjuvant or plus CpG DNA yielded no detectable L1-specific antibodies (Figure 2A) . By contrast, there was a clear humoral response in mice vaccinated with rAAV5-L1/E7 plus HLT (3/5 mice were positive) or -even more pronounced -with MPL as adjuvant (5/5 mice were positive; Figure 2A) . Surprisingly, in the case of rAAV9-L1/E7, addition of CpG or HLT as an adjuvant had a negative effect on humoral immunity. Also, combination with MPL did not significantly stimulate the humoral immune response obtained by vaccination with this vector. In contrast to the development of antibodies, there were only marginal effects of the different adjuvants on the CTL response ( Figure 2B and 2C) . A slight reduction in the L1-and E7-specific cellular immune response obtained with rAAV9 and CpG should be noted.
Heterologous prime boost or combined vaccination with rAAV5 and rAAV9 strongly enhances the humoral immune response
We reasoned that another way to improve the prophylactic capacity of the combined vaccine based on the rAAV-L1/E7 vectors could be achieved by priming with rAAV9-L1/E7 followed by a boost with rAAV5-L1. Alternatively, a single immunization with a mixture of the two vectors was envisaged. Five C57BL/6 mice per group were intranasally primed with rAAV9-L1/E7 and boosted with rAAV5-L1 7 days later (5×10 10 gp/dose). Another group was immunized intranasally once with rAAV5-L1 plus rAAV9-L1/E7 (5×10 10 gp/each). Mice vaccinated with two doses of 5×10 10 gp/dose rAAV9-L1/ E7 were used as controls. After 12 weeks, sera were analysed by ELISA for IgG HPV16 L1-specific antibodies. Figure 4A shows that both combinations induced a strong improvement of the humoral immune response with titres far above those achieved by application of adjuvant (Figure 2A ) or by expression of L1 alone (Figures 1 and 3A) . Also, the L1-specific CTL response was slightly enhanced by this regimen, whereas CTL response to E7 remained unchanged ( Figure 4B) .
The sera obtained after heterologous prime boost or mixed vaccination showed a highly improved neutralization capacity in the HPV16 pseudovirion assays ( Figure 4B ) as compared with sera obtained by vaccination with one serotype vector alone ( Figure 1B) . The dilutions that still lead to 50% neutralization were similar to the high values obtained after rAAV5-L1 or rAAV9-L1 vaccinations ( Figures 3C and 4B ).
Mice vaccinated with rAAV-L1/E7 are protected against HPV16 E7-positive tumour cells
Next we analysed whether vaccination with rAAV-L1/ E7 can prevent tumour growth in mice. A total of 10 C57BL/6 mice per group were vaccinated twice intranasally with rAAV5-L1/E7 or rAAV9-L1/E7 (5×10 10 gp/dose). At 9 weeks after the vaccination, mice were challenged subcutanously in the flank with 5×10 5 C3 cells (HPV16 L1-and E7-positive). Tumour growth was monitored by visual inspection and palpation twice a week. As shown in Figure 5A , immunization with rAAV5-L1/E7 and rAAV9-L1/E7 induces a higher percentage of tumour-free mice compared with the control. This protection might be the result of a CTL response against L1 or E7. Because only E7 is consistently expressed in HPV-associated high-grade lesions, we tested whether the vaccinated animals were also protected against a challenge with TC-1 cells expressing only E6 and E7 but not L1 [28] . Mice protected in the C3 cell challenge experiment were rechallenged by injection of 5×10 5 TC-1 cells. For control, untreated animals (n=10), animals treated with rAAV5-GFP (n=10) or with PBS (n=10) were inoculated with the same amount of tumour cells. Figure 5B shows that all animals vaccinated with rAAV5-L1/E7 or rAAV9-L1/ E7 were completely protected against the growth of the second tumour cell line indicating that the E7-directed CTL response was sufficient for tumour protection.
Discussion
Our analysis of the potential of rAAV serotype vectors for nasal vaccination revealed a number of promising aspects towards the development of a combined prophylactic and therapeutic HPV vaccine. We developed conditions that provided a strong humoral and cellular immune response to an L1/E7 fusion protein expressed by rAAV5 and rAAV9 vectors after non-invasive intranasal application. This was achieved by applying a mixture of serotype 5 and 9 vectors or by a heterologous prime boost. The addition of adjuvants also strongly improved the humoral immune response to L1 when the L1/E7 fusion gene was expressed by rAAV5 vectors. Our analyses also showed, for the first time, that rAAV serotypes 5, 8 and 9 behave strikingly different with regards to vaccination efficiency using the intranasal route and in synergizing with different adjuvants.
We have chosen to study the performance of rAAV vectors of serotypes 5, 8 and 9 in genetic vaccinations. According to our protocol for vector production [11] , the L1 or L1/E7 genes are expressed together with the helper virus proteins leading to L1 and L1/E7 VLPs or aggregates within the 293T producer cells. Because these structures cofractionate with recombinant AAVs during vector purification and, thus, might obscure the effect of the rAAV-transduced HPV genes, we have developed a protocol for the suppression of L1 expression in the 293T producer cells by short hairpin RNAs, combined with physical HPV-specific depletion of the particles by trypsin and Na 2 HCO 3 (Nieto et al., unpublished observations). Because these treatments were associated with a substantial reduction of vector recovery and, as shown in a comparative immunization experiment, the addition of 19 ng/dose of L1/ E7 particles does not influence the immunogenicity of HPV rAAV, we performed all experiments without the depletion of L1/E7 particles from the rAAV vector preparations. However, because a few ng of L1 VLP applied subcutaneously elicits a weak humoral response [26] , L1 VLPs were depleted from the rAAV vector preparations in all experiments to a non-detectable level (VLP<0.8 ng/dose) by the ELISA applied.
It has previously been shown that rAAV5 and rAAV8 belong to the most effective serotypes for lung tissue transduction [16, [29] [30] [31] . AAV5 was also efficient in dendritic cell transduction in vitro and in vivo [32] and showed an excellent humoral and cellular immune response to L1 when applied intranasally [16] . For rAAV9, extraordinary high transduction efficiencies in a number of tissues have been reported [33] [34] [35] ; however, vectors of this serotype have not been used for vaccination purposes so far. Vaccination with rAAV9 generated a strong humoral and cellular immune response, whereby the humoral response in serum and vaginal washes (but not the cellular response) was even stronger than with rAAV5. In particular, the generation of L1-specific antibodies was superior with rAAV9 when the fusion gene (L1/E7) was expressed. We failed to detect an immune response with rAAV8 vectors transducing the L1/E7 fusion gene. Antibodies against rAAV8 capsids indicated successful vector delivery; however, transgene expression could not be detected in lung tissue (data not shown). In recent reports, transduction of murine nasal airway epithelia was performed with a number of different rAAV vectors, including rAAV5, rAAV8 and rAAV9 [36, 37] . The best transduction was achieved with rAAV5, rAAV6 and rAAV9 in addition to some newly isolated vector types [36] , whereas rAAV8 showed only poor gene delivery [36] . The lower immunogenicity of the L1/E7 fusion protein product together with a reduced expression level in nasal tissue using the rAAV8 vectors might explain our negative result with this vector.
A major limiting factor for rAAV-mediated genetic vaccination can be the prevalence of anti-AAV capsid antibodies, which prevent transgene expression. Neutralizing antibodies against AAV5 are rather rare in the human population (10-20%) [38] , whereas the prevalence of AAV9 antibodies has not been described so far. Interestingly, AAV9 vectors could be readministered to the lung of mice in the presence of high circulating neutralizing antibody levels [37] suggesting that nasal reapplication might also be possible. It should also be mentioned that the anti-rAAV9 antibody titres detected after intranasal vaccination were 10-50-fold lower than the antibody titres against rAAV5. Furthermore, mice immunized with rAAV5-GFP vectors could be readministrated successfully with rAAV5-L1 after 60 weeks [16] . Together with the observation that antibodies directed against different AAV serotypes are not cross-neutralizing, these data support the perspective that rAAV vaccination is possible even in populations with AAV antibody prevalence.
In order to improve vaccination with the L1/E7 fusion gene, we tried to stimulate the immune response by three types of adjuvants targeting different levels of the innate immune response [39] . CpGs and MPLs activate pathogen recognition receptors (Toll-like receptor [TLR]-9 and TLR-4, respectively); HLT has been suggested to increase the B7 costimulatory molecule expression [40] . Although L1-specific serum IgG titres generated by rAAV5-L1/E7 vaccination could be augmented by HLT and MPL, neither adjuvant improved the serum antibody titres elicited by rAAV9-L1/E7. This might indicate different pathways of immune activation by the two rAAV vectors. Because of the strikingly different response of rAAV5 and rAAV9 vectors to the adjuvants, one must postulate that the use of different cell entry receptors by the two vectors [41, 42] might lead to the infection of different cell types or to different intracellular pathways of gene transduction. As shown by Limberis and Wilson [37] , rAAV9 leads to the transduction of alveolar cells and a few conducting airway cells, whereas AAV5 transduced alveoli cells and conducting airways cells. Presently, it is unknown whether the rAAV vectors directly reach immune cells in the nasal mucosa. Coapplication of CpGs repressed the immune reaction generated by rAAV9 and did not improve rAAV5-L1/E7 immunogenicity indicating that TLR-9 stimulation might be counter-effective in eliciting an immune response with these vectors. It has been reported that systemic application of CpG prior to the antigen can lead to suppression instead of stimulation of the immune reaction [43] . Coapplication of CpGs with rAAV vectors will in fact be a pre-application because expression of the antigen starts 1-2 weeks later.
The major goal of this project was to explore the potential of an rAAV vector-based nasal vaccination combining prophylactic and therapeutic effects. In a previous study, we analysed the performance of different L1/E7 fusion genes in DNA vaccination [11] . We used an L1/E7 gene (which codes for an L1/E7 fusion protein that is slightly different from the L1/E7 protein), which assembles into CVLPs [6] and elicits humoral and cellular immune responses [9, 16] . Sedimentation analyses of the protein derived from the fusion gene used in this study suggested that some kind of L1 aggregates, rather than VLPs or capsomers, are being formed [11] . Expression of this construct by rAAV5 or rAAV9 vectors triggered a lower humoral immune response compared with vaccination with L1 rAAVs suggesting a lower immunogenicity of the L1/E7 fusion gene product. It is unlikely that a lower level of expression accounts for this difference as the cellular immune response to L1 was only slightly weaker than after the expression of the unfused L1. In addition, the humoral immune response to L1 following heterologous rAAV5-L1/rAAV9-L1/E7 prime boost or the mixed serotype vaccination could be pushed to values that exceeded those obtained by expression of L1 alone or those achieved by vaccination with VLPs. Also, some of the tested adjuvants improved the humoral immune response obtained with rAAV5 significantly, which might open further improvements of the immune response in a mixed vaccination approach. The cellular immune response was not enhanced in heterologous prime boost or adjuvant experiments in support of the observation by Lin et al. [44] that CTL proliferation in response to an antigen by rAAV is not augmented by a challenge with the same antigen. In contrast to the data by these researchers, however, we did not observe a reduction of the T-cell response in the prime boost experiment.
We were unable to test for an effect against existing tumours because growth of the inoculated tumour cells was too fast in comparison to the antigen expression kinetics of the rAAV vectors. In line with our observation on the induction of HPV16-specific CTLs ( Figure 1C) , we observed that vaccination with rAAV5-L1/E7 was slightly more effective than with rAAV9-L1/E7. Because the ELISPOT assays demonstrated a cellular immune response against both the L1 and the E7 proteins, we assume that the clinically more relevant E7-specific response also contributed to the antitumor effect against C3 cells. This was confirmed by the observation that all tumour-free animals were completely protected against a second challenge with TC-1 cells expressing only E6 and E7 oncogenes (and not the structural L1 gene). However, we cannot completely exclude that clearance of C3 cells served to boost the E7 T-cells or induced a response against an undefined cellular protein that is shared by both tumour cells. In any case, our results argue against the conclusion that CTL responses elicited by rAAV vectors are aberrant and might lead to anergy caused by T-cell exhaustion [44] rather than to an effective T-cell response against the vaccination antigen. In all experiments, the T-cell responses obtained with rAAV vaccination were more pronounced than with VPLs or CVLPs, confirming the superior effect of DNA versus protein immunization [45] .
Altogether, our study demonstrates that the expression of HPV16 L1/E7 fusion genes in combination with L1 alone using rAAV5 and rAAV9 vectors elicits humoral and cytotoxic immune responses after non-invasive application; thus, this combined prophylactic and therapeutic vaccine meets some of the demands of future HPV vaccines. As the performance of rAAV vectors also tolerates lyophilization and resuspension in water [16] , a further limitation of current vaccines -the requirement of cold storage -can be overcome. Especially the dramatic stimulation of the B-cell response in heterologous prime boost or mixed vaccination with rAAV5 and rAAV9 vectors opens a new field of further vaccine development on the basis of rAAV.
